CGON: Durable efficacy, workflow fit, and imminent PIVOT-006 data drive optimism for cretostimogene
Key topics included robust manufacturing and inspection readiness for cretostimogene, strategic launch planning, and differentiation through durable efficacy and workflow advantages. Near-term catalysts include PIVOT-006 data and label expansion, supported by a strong cash position.Based on CG Onco…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.